Core Competence
Expertise across sterile and non-sterile dosage forms
Our formulation development capability covers both sterile and non-sterile pharmaceutical dosage forms. On the sterile side, this includes powder for injection, ready-to-use infusion bags and pre-filled syringes, lyophilized products and lyo-to-liquid conversions, and ophthalmic solutions and suspensions. On the non-sterile side, we develop immediate-release (IR) solutions and suspensions as well as sustained-release (SR) suspensions. This experience is reflected in our technology transfers to date: 8 liquid orals, 7 injectables, 5 ophthalmics and 4 semisolids.
- Sterile
- Non-sterile
24 products transferred across dosage forms
Platforms built around patient and therapy needs
Each of our platform technologies is aimed at a specific limitation of existing therapies, from dosing frequency and treatment adherence to solvent use and the oral absorption of poorly soluble drugs.
Oral Liquid Platform
Addressing dysphagia
Sustained Release Liquids
Addressing frequent dosing
Biodegradable Depot Injections
Reducing frequent injection dosing
Sustained Release Injection Platform
Addressing treatment adherence
Solvent Free Nanosuspensions
Avoiding harsh solvent usage
Tumor Targeting Platform
Focusing cancer treatments
Injection to Oral Therapies
Oral absorption of poorly soluble drugs
Structure Modification Platform
Improving toxicity/efficacy
Experience with complex sterile products
Our team has been involved in complex products including:
- Doxorubicin liposomal injection
- Amphotericin B liposomal lyophilized injection
- Penicillin G benzathine sterile injectable suspension
- Cefquinome LC/DC semi-solid intramammary sterile injection
- Ceftiofur Na powder filling sterile injection
Explore the labs behind our capabilities
Formulation, stability, analytical and microbiology areas.